{"id":5171,"date":"2019-05-29T09:34:11","date_gmt":"2019-05-29T07:34:11","guid":{"rendered":"https:\/\/www.adssc.org\/en\/?p=5171"},"modified":"2020-06-23T11:32:58","modified_gmt":"2020-06-23T09:32:58","slug":"the-dead-sea-and-arava-science-center-is-on-the-forefront-of-science-leading-successfuly-pre-clinical-studies-in-the-neurodegenerative-als-disesae","status":"publish","type":"post","link":"https:\/\/www.adssc.org\/en\/the-dead-sea-and-arava-science-center-is-on-the-forefront-of-science-leading-successfuly-pre-clinical-studies-in-the-neurodegenerative-als-disesae\/","title":{"rendered":"The Dead Sea and Arava Science Center is at the forefront of science, leading successfully pre- clinical studies in the neurodegenerative ALS disease"},"content":{"rendered":"<div>In the last few years, the laboratory of <a href=\"https:\/\/www.adssc.org\/en\/reserchers-niva-russek-blum-phd\/\" target=\"_blank\" rel=\"noopener noreferrer\">Dr. Niva Russek-Blum<\/a> located in the Central Arava branch, is leading a reserach in zebrafish carrying a mutation in the SOD1 gene, a valid model for human ALS disease.<\/div>\n<div>In a research led by Dr. Russek- Blum, in collaboration with the Israeli company Neurosense therapeutics, Dr. Gary Armstrong from the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Prof. Jeremy Shefner from the Barrow Neurological Institute at Dignity Health St. Joseph\u2019s Hospital and Medical Center in Phoenix, remarkable results in the ALS zebrafish model were exhibited, using a unique drug combinationation.<\/div>\n<div>The company is now spearheading to the clinical phase, initiating a compassionate study while preparing to begin a phase II clinical study in ALS patients, to show its efficacy in humans.<\/div>\n<div>\n<p>To learn more about the study&#8217;s results please see the movie.<\/p>\n<\/div>\n<div>\n<div style=\"width: 1280px;\" class=\"wp-video\"><video class=\"wp-video-shortcode\" id=\"video-5171-1\" width=\"1280\" height=\"720\" preload=\"metadata\" controls=\"controls\"><source type=\"video\/mp4\" src=\"https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/New-Hope-for-ALS-Patients.mp4?_=1\" \/><a href=\"https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/New-Hope-for-ALS-Patients.mp4\">https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/New-Hope-for-ALS-Patients.mp4<\/a><\/video><\/div>\n<p>Dr. Russek- Blum Laboratory:<br \/>\n<img fetchpriority=\"high\" decoding=\"async\" class=\"alignnone size-full wp-image-4418\" src=\"https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2018\/11\/NIVA1.jpg\" alt=\"\" width=\"500\" height=\"281\" srcset=\"https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2018\/11\/NIVA1.jpg 500w, https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2018\/11\/NIVA1-300x169.jpg 300w\" sizes=\"(max-width: 500px) 100vw, 500px\" \/><\/p>\n<p><img decoding=\"async\" class=\"alignnone size-large wp-image-5175\" src=\"https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/Niva_L-1024x768.jpg\" alt=\"\" width=\"1024\" height=\"768\" srcset=\"https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/Niva_L-1024x768.jpg 1024w, https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/Niva_L-600x450.jpg 600w, https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/Niva_L-300x225.jpg 300w, https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/Niva_L-768x576.jpg 768w, https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/Niva_L-160x120.jpg 160w, https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2019\/05\/Niva_L.jpg 1400w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>In the last few years, the laboratory of Dr. Niva Russek-Blum located in the Central Arava branch, is leading a reserach in zebrafish carrying a mutation in the SOD1 gene, a valid model for human ALS disease. In a research led by Dr. Russek- Blum, in collaboration with the Israeli company Neurosense therapeutics, Dr. Gary [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4419,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[155],"tags":[],"class_list":{"0":"post-5171","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-news-and-media"},"jetpack_featured_media_url":"https:\/\/www.adssc.org\/en\/wp-content\/uploads\/2018\/11\/Niva2.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/posts\/5171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/comments?post=5171"}],"version-history":[{"count":3,"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/posts\/5171\/revisions"}],"predecessor-version":[{"id":5192,"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/posts\/5171\/revisions\/5192"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/media\/4419"}],"wp:attachment":[{"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/media?parent=5171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/categories?post=5171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.adssc.org\/en\/wp-json\/wp\/v2\/tags?post=5171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}